Kiromic BioPharma Advances Deltacel-01 Clinical Trial to Expansion Phase
Houston-based biopharmaceutical company, Kiromic BioPharma, Inc. has announced its plans to advance the Deltacel-01 Phase 1 clinical trial to the Expansion Phase. This decision comes as a result of a positive assessment from the Deltacel-01 Safety Monitoring Committee (SMC), which reviewed safety and efficacy data collected thus far and confirmed favorable results and optimal dosage.
The Deltacel-01 trial focuses on evaluating Deltacel (KB-GDT-01), Kiromic’s allogeneic and off-the-shelf Gamma Delta T-cell (GDT) therapy. The therapy is being tested in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have not responded to standard treatments.
In a previous announcement, Kiromic BioPharma reported favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase 1 clinical trial. These promising results further validated the efficacy of Deltacel (KB-GDT-01) in treating stage 4 NSCLC patients who have failed to respond to conventional therapies.
The fourth patient enrolled in the clinical trial also showed favorable safety and tolerability, along with early signs of efficacy. The preliminary results of Deltacel-01 Phase 1 trial have raised hopes for improved outcomes in patients with advanced NSCLC.
The Expansion Phase of the clinical trial marks a significant step forward for Kiromic BioPharma, as it demonstrates the considerable potential of Deltacel (KB-GDT-01) in addressing the unmet medical needs of patients with metastatic NSCLC. By advancing to the next stage, the company aims to gather more substantial data and strengthen the evidence for the therapy’s effectiveness.
Kiromic BioPharma’s commitment to developing innovative therapies for cancer treatment is reflected in the progress of the Deltacel-01 Phase 1 clinical trial. The positive assessment by the Safety Monitoring Committee underscores the potential of Deltacel (KB-GDT-01) as a viable treatment option for patients with advanced NSCLC.
Comments